16 Pharmaceuticals Stocks to Sell Now

16 Pharmaceuticals Stocks to Sell Now

This week, the overall grades of 16 Pharmaceuticals stocks are lower, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Eli Lilly and Company (LLY) gets weaker ratings this week as last week’s C drops to a D. Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. For more information, get Portfolio Grader’s complete analysis of LLY stock.

This is a rough week for Prestige Brands Holdings, Inc. (PBH). The company’s rating falls to D from the previous week’s C. Prestige Brands Holdings, Inc. distributes over-the-counter healthcare and household cleaning products to retail stores in the United States, Canada and other international markets. The company also gets F’s in earnings growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of PBH stock.

This week, Impax Laboratories, Inc. (IPXL) drops from a D to a F rating. Impax Laboratories, Inc. develops, manufactures, and markets both proprietary and multi-source pharmaceutical products utilizing its drug delivery technologies. The company also gets F’s in sales growth, earnings surprise, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of IPXL stock.

NeuroDerm Ltd. (NDRM) slips from a C to a D this week. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of NDRM stock.

Paratek Pharmaceuticals Inc (PRTK) declines this week from a D to a F. The company also gets F’s in earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of PRTK stock.

Omeros Corporation’s (OMER) rating weakens this week, dropping to a D versus last week’s C. Omeros Corporation is a biopharmaceutical company developing a pipeline of product candidates for use in orthopedics, rheumatology, urology, cardiovascular medicine, general surgery and pain management. The company also gets F’s in free cash flow. For more information, get Portfolio Grader’s complete analysis of OMER stock.

Slipping from a D to a F rating, Sucampo Pharmaceuticals, Inc. Class A (SCMP) takes a hit this week. Sucampo Pharmaceuticals, Inc. Class A is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary drugs based on prostones, a class of compounds derived from functional fatty acids that occur naturally in the human body. The company also gets F’s in operating margin growth, earnings growth, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of SCMP stock.

Akari Therapeutics Plc Sponsored ADR (AKTX) experiences a ratings drop this week, going from last week’s B to a D. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of AKTX stock.

Zynerba Pharmaceuticals Inc (ZYNE) earns a F this week, moving down from last week’s grade of D. The company also gets F’s in sales growth, earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ZYNE stock.

This week, Agile Therapeutics, Inc.’s (AGRX) rating worsens to a D from the company’s C rating a week ago. The company also gets F’s in earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of AGRX stock.

Neos Therapeutics, Inc. (NEOS) is having a tough week. The company’s rating falls from a D to a F. The company also gets F’s in earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of NEOS stock.

Endocyte, Inc. (ECYT) experiences a ratings drop this week, going from last week’s D to a F. Endocyte, Inc. is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ECYT stock.

Cardiome Pharma Corp. (CRME) gets weaker ratings this week as last week’s D drops to a F. Cardiome Pharma Corp. focuses on the discovery, development, and commercialization of drugs to treat or prevent cardiovascular and other diseases. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CRME stock.

Auris Medical Holding AG (EARS) slips from a C to a D this week. The company also gets F’s in earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of EARS stock.

DURECT Corporation’s (DRRX) rating weakens this week, dropping to a D versus last week’s C. DURECT Corporation is a specialty pharmaceutical company that develops pharmaceutical systems technologies based on its proprietary drug delivery technology platforms. The company also gets F’s in sales growth, earnings surprise, and return on equity. For more information, get Portfolio Grader’s complete analysis of DRRX stock.

This week, Acura Pharmaceuticals, Inc.’s (ACUR) rating worsens to a F from the company’s D rating a week ago. Acura Pharmaceuticals, Inc. engages in the research, development, and manufacture of pharmaceutical product candidates utilizing its proprietary Aversion and Impede technologies. The company also gets F’s in sales growth, earnings growth, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ACUR stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/08/16-pharmaceuticals-stocks-to-sell-now-2/.

©2020 InvestorPlace Media, LLC